HOME >> MEDICINE >> NEWS
Infliximab could offer long-term benefits to people with Crohns disease

Sustained use of the drug infliximab could offer substantial clinical benefit to people with Crohns disease, conclude authors of a study in this weeks issue of THE LANCET.

Crohns disease is a chronic inflammatory disorder of the intestines. Patients often have to be treated with steroids, which are associated with severe side-effects. Previous research has suggested that the drug infliximab could reduce disease symptoms in the short term; Stephen Hanauer and colleagues from the University of Chicago, USA, investigated whether treatment with infliximab every two months could be more effective in reducing the symptoms of Crohns disease in the longer term compared with a single infusion of the drug.

355 patients with severe Crohns disease from the USA, Europe, and Israel who responded within two weeks to an initial 5 mg/kg intravenous infusion of infliximab took part in the study. They were randomly assigned repeat infusions of placebo, repeat infusions of 5 mg/kg infliximab, or 10 mg/kg infliximab (after two treatments with 5mg/kg infliximab). Treatment took place at randomisation, after one month, and thereafter every two months for a year.

More than twice as many people given infliximab every two months were in remission after 30 weeks compared with patients who only received initial infliximab treatment followed by placebo. Patients given sustained infliximab responded for longer (for 38 and 54 weeks for 5mg/kg and 10mg/kg regimens, respectively) compared with patients given placebo (who only responded to treatment for an average of 19 weeks). Patients given infliximab were also more likely to discontinue use of steroids compared with those given placebo.

Stephen Hanauer comments: This study was important to demonstrate a sustained response to maintenance treatment with infliximab in Crohns disease, similar to the results with maintenance treatment for rheumatoid arthritis. After a series of inductive infusions at baseline, 2 and
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
2-May-2002


Page: 1 2

Related medicine news :

1. Charcoal and forest management could reduce greenhouse gas levels & save lives in Africa
2. Novel therapy tested in mice could chase away cat allergies
3. Costs of antidepressants could have funded effective alternatives
4. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results
5. Blood pressure treatment could cut risk of strokes and heart attacks
6. Proteins found in urine of pregnant women could help diagnose preeclampsia
7. Three out of the four million newborn babies who die each year could be saved
8. Increasing physician volume requirement could improve mammogram accuracy, study concludes
9. Chemicals in apples could reduce the risk of breast cancer, Cornell study in rats suggests
10. Training could remove racial bias from police reactions
11. Test could improve detection of prion disease in humans

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... Steven Douglas ... Taste of South Florida Event, an upscale fundraiser held in South Florida. The Inaugural ... and guests alike. This year the event will be held in a new, more ...
(Date:2/9/2016)... ... February 09, 2016 , ... URise Products announces ... mobility device, the StandUp Walker. Made entirely in the USA, the StandUp Walker ... years. , StandUp Walker’s novel patent-pending design offers 2-in-1 benefits of a ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus ... the continuation of the ‘Pay It Forward’ program into 2016. BioPlus partners with ... our specialty pharmacy. , “Since our Pay It Forward program began, we ...
(Date:2/9/2016)... Milwaukee, WI (PRWEB) , ... February 09, 2016 ... ... Bon-Ton, Bergner’s, Boston Store, Carson’s, Elder-Beerman, Herberger’s and Younkers department stores, announced it ... Medical College of Wisconsin Cancer Center, Holden Comprehensive Cancer Center at the University ...
(Date:2/9/2016)... Florida (PRWEB) , ... February 09, 2016 , ... ... cold therapy products, announced today the introduction of the newly designed, innovative shoulder ... comfort and better cold therapy coverage for the injured arm and shoulder to ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... its fourth quarter and full year 2015 financial ... therapeutic genome editing," said Edward Lanphier, Sangamo,s president ... (ZFN) technology leads the therapeutic genome editing field ... to move our ground-breaking genome editing programs through ...
(Date:2/9/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced ... full year financial results on Tuesday, February 23, 2016, ... will host a live audio webcast immediately following the ... fourth quarter and full year 2015 financial results and ... 2016 financial results. www.jazzpharmaceuticals.com .  Please connect ...
(Date:2/9/2016)... Sciences Ltd. (NYSE:  AXON), a leading clinical-stage biopharmaceutical ... announced further details of three new clinical trials ... Lewy body dementia, a disease affecting approximately 1.4 ... the three studies were recently initiated and the ... In addition, the Company reported financial results for ...
Breaking Medicine Technology:
Cached News: